ICER Identifies Most Significant 2019 US Drug-Price Hikes

January 12, 2021

The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States. Among the top drugs with price increases in 2019 that had substantial effects on US spending, ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known. The 2019 unsupported price increases on these seven treatments, even after pharmaceutical rebates and other concessions, cost the US health system an additional $1.2 billion beyond what would have been spent if their net prices had remained flat.

“Thanks in part to increased public scrutiny on annual price hikes, higher pharmaceutical rebates, and an uptick in generic drug utilization, average net prices on brand-name drugs have remained relatively stable in the US over the past two years,” said David Rind, MD, ICER’s Chief Medical Officer. Read more here.

Share This Story!